Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
Kiniksa Pharmaceuticals (KNSA) will report third quarter 2026 financial results during a conference call and live webcast on October 27, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kiniksa Pharmaceuticals (KNSA) will report third quarter 2026 financial results during a conference call and live webcast on October 27, 2026. The event begins at 8:30 a.m. Eastern Time and will also cover recent portfolio execution. The webcast will be available through the Investors & Media section of Kiniksa’s website, with a replay available within approximately 48 hours after the event.
Key Figures
- Results reporting call
- October 27, 2026, 8:30 a.m. Eastern Time
- Third quarter 2026 financial results and recent portfolio execution
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.
Every Second Counts! ®
Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com
